Jaguar Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on March 18, 2025. The report details the formal approval and filing of a reverse stock split of the Company's common stock, following a special meeting of stockholders held on March 13, 2025.
Key Financial Metrics
This filing is a corporate action report and does not contain financial performance data. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
- Reverse Stock Split Approval: The Board of Directors approved a one-for-twenty-five (1:25) reverse stock split, within the range previously authorized by stockholders (1:15 to 1:40).
- Effective Date: The split will become effective at 12:01 am Eastern Time on March 24, 2025.
- Share Reclassification: Every 25 shares of outstanding common stock will be reclassified into 1 share. Par value per share remains unchanged.
- Equity Adjustments: Outstanding stock options and warrants will be adjusted proportionately, with exercise prices increasing and share counts decreasing. No fractional shares will be issued; cash will be paid in lieu of fractions.
- Trading Details: Trading on The Nasdaq Capital Market will resume on a split-adjusted basis on March 24, 2025, under the new CUSIP number 47010C888.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future performance, or specific risk factors beyond the standard implications of a reverse stock split. The primary purpose is to disclose the amendment to the Certificate of Incorporation and the mechanics of the share consolidation.
Investor Verification Checklist
- Confirm the effective time of the reverse stock split is March 24, 2025, at 12:01 am ET.
- Verify the new CUSIP number (47010C888) for trading purposes.
- Check broker statements for the conversion of 25 pre-split shares into 1 post-split share.
- Review the treatment of fractional shares, which will be settled in cash rather than issued as stock.
- Confirm adjustments to the exercise price and share count of any held stock options or warrants.